1. Introduction {#sec1}
===============

Human and animal health threats from coronaviruses have been present over time. Uncontrolled porcine, bat, mouse, bovine, avian and human coronaviruses dispersal can impact both global public health and economic stability. As early as 2002, beta coronaviruses (CoV) zoonotic outbreaks have been reported ([@bib124]), including severe acute respiratory syndrome coronavirus (SARS)-CoV in 2002--2003 ([@bib90]), Middle East respiratory syndrome (MERS)-CoV in 2012 ([@bib191]) and, in late 2019, the novel SARS-CoV-2 ([@bib38]). The porcine epidemic diarrhea virus (PEDV) should also be included ([@bib20]). Coronaviruses have been associated with various ailments, including respiratory, gastrointestinal, and central nervous system diseases both in humans and animals, impacting not only human health but also economic stability ([@bib128]). The transmission model, clinical manifestations, pathogenesis and treatment of coronavirus disease have been recently reviewed ([@bib38]).

[Fig. 1](#fig1){ref-type="fig"} shows an anthropological and scientific approach for the evaluation of the association of the global production of crude oil, atmospheric pollutants, and pesticides with the population growth and chronic diseases trends ([@bib56]). We emphasize that long-term exposure to anthropogenic pollutants, among other risk factors, may have a positive association with chronic diseases such as neurodegenerative disorders (e.g., Parkinson\'s disease) and diabetes ([@bib36]; [@bib141]), breast cancer ([@bib33]), non-Hodgkin\'s lymphoma ([@bib69]), cancer ([@bib15]), leukemia ([@bib25]), obesity ([@bib121]), congenital heart defects ([@bib101]), hypertension ([@bib180]. Raised blood pressure," n. c.d.) and increased vulnerability to microbial and viral infections and their mortality ([@bib48]).Fig. 1Association of global crude oil, atmospheric pollutants and pesticide production with population growth and chronic disease trends.Fig. 1

While increases in disease correlate with increases in anthropogenic pollutants, correlation is not causation. For causation, mechanisms need to be identified that link pollutants to eventual diseases credibly. The remainder of this paper presents evidence of the biological mechanisms that link the pollutants to myriad diseases of interest, especially through adverse impacts on the immune system.

2. Influence of environmental risk factors on the immune system {#sec2}
===============================================================

The immune system can be the target of many chemical, biological, and physical agents that may elicit adverse effects on the host\'s health; however, it is still unknown the extent to which low exposure to environmental toxic stimuli may adversely affect human health. The proinflammatory and immunomodulatory properties of many toxic stimuli may have limited effects on the immune system, unless exposure occurs early in life or concurrently with infections or malignant diseases. Under these circumstances, there is an increased risk of progression from exposure to infection, autoimmune diseases, or even cancer. Nevertheless, the compensatory mechanisms of the immune system limit the potential health impact at the individual level, although minor immunomodulatory effects may have an impact at the population level by contributing to increased burden of diseases ([@bib61]).

Environmental factors are believed to contribute to the increased prevalence of allergies and autoimmune diseases, many of which are due to the activity of Th17 T cells. These Th17 T cells are a newly-identified helper T-cell subset characterized by production of interleukin (IL)-17 and IL-22, as observed in experimental autoimmune encephalomyelitis ([@bib170]) and more recently in COVID-19 patients in China. The immunologic response of barrier organs (e.g., skin, gut, lung, eyes, and oral and genital mucosal tissues) against pathogenic microbes and protein antigens, including SARS-CoV-2, is disrupted in hematopoietic stem cells, innate immune system cells, as well as in T-cell subsets and B cells.

Chronic exposure to environmental chemicals has been shown to suppress or enhance immune responsiveness, depending on factors such as dose, timing, and route of exposure. For example, environmental immunology has led to the understanding of how xenobiotics (such as polycyclic aromatic hydrocarbons (PAH)) acting via immunomodulatory signaling pathways, and specifically the aryl hydrocarbon receptors (AhR), may adversely affect the developing immune system (which seems to be more sensitive to environmental insults than the adult immune system ([@bib89])). Immunotoxicology can also be beneficial in investigating whether an epidemic/pandemic, or a chronic disease, is idiopathic or a deterministic event reflecting cumulative adverse effects on the immune system. Understanding the impact of environmental toxic stimuli on the immune response ultimately contributes to improving public health.

Many decades ago, infectious diseases were the main cause of mortality globally. With the increased influx of modern technology and its under-regulated adverse byproducts into the environment and workplace, non-communicable diseases have replaced infectious diseases as the leading cause of mortality world-wide. However, infectious diseases are still amongst the top five causes of global death ([@bib185]).

Xenobiotics, whether natural or anthropogenic, can readily interact with the immune system, leading to a suppressed or enhanced immune responsiveness ([@bib45]). Of increasing concern is the observed reduced immune response to viral and bacterial infection, as well as myelosuppression and thymic dysfunction. For example, coplanar polychlorinated biphenyls (PCBs) and dioxins have been shown to mediate their effect via the AhR. Such effects include diminished humoral antibody responses, humoral immune suppression ([@bib152]), severe thymic atrophy, and reduced cell-mediated immunity, to name a few.

2.1. The AhR signaling pathway in immune system responses against xenobiotics and viruses {#sec2.1}
-----------------------------------------------------------------------------------------

The AhR is an evolutionarily ancient protein that can be activated or inhibited by various types of exogenous and endogenous ligands. While AhR canonical signaling has been identified as a primary mediator of biological responsiveness to environmental chemicals, alternative signaling events are increasingly being understood to mediate the physiological effects of AhR ([@bib79]). AhR is a cytosolic signal sensor and transcription factor that translocates into the nucleus upon binding to planar aromatic hydrocarbons. In addition, AhR signaling is intricately involved in fine-tuning distinct immune responses, particularly at environmental interfaces where endogenous and exogenous AhR ligands accumulate ([@bib137]). For example, AhR activity has been documented to be a key determinant of T helper (Th) cell differentiation. Notably, ligands with differential AhR agonist activity may have opposing effects on Th cell differentiation, demonstrating the finely tuned regulation of this transcription factor at the ligand-binding level ([@bib137]).

The AhR signaling pathway plays a key role in innate and adaptive immune responses, and controls transcription of xenobiotic-metabolizing enzymes like cytochrome P450 family members (e.g., CYP1A1 and CYP1B1) ([@bib155]). Exogenous AhR ligands include environmental toxic stimuli (e.g., dioxin), bacterial metabolites, or naturally occurring ligands, such as dietary ligands (e.g., flavonoids and glucosinolates), abundantly found in plants ([@bib106]). Starting from infancy, AhR levels in hepatic, lung, and thymic cytosol slowly decline with age. Thus, while innate immune cells in children have high expression of AhR, immune cells in adults have conservative to low AhR expression ([@bib43]), representing a potential important highlighted finding in COVID-19 prevalence in adults.

It is recognized that polyhalogenated aromatic hydrocarbons (PAHs), dioxins, and biphenyls can activate AhR given their structural resemblance to physiologic ligands. This, in turn, may increase the metabolic turnover of physiologic ligands, thus decreasing their half-life. As a result, uncontrolled or persistent activation of the AhR by exogenous small molecules or UVB radiation may alter the tightly controlled and transient AhR-regulated cell functions ([@bib43]).

AhR signaling is dependent of the formation of complexes with other proteins (cross-talk), such as AhR-interacting protein (AIP), estrogen receptor (ER), inducible nitric oxide synthase (iNOS), matrix metalloproteinase (MMP), nuclear factor-κB (NF-κB), prostaglandin synthase (PGHS), retinoblastoma protein (RB), tumor necrosis factor α (TNF-α) and xenobiotic-metabolizing enzymes (XME) ([@bib8]).

AhR canonical and noncanonical signaling pathways can regulate master regulatory transcriptional factors, such as the nuclear factor (NF)-κB promoter and signal transducer and activator of transcription (STAT). These transcriptional factors regulate the general transcriptional machinery to induce transcriptional, post-translational and epigenetic expression of selective inflammatory genes ([@bib11]). Additionally, cytosolic AhR and NF-kB regulate calcium-related genes, increasing rapidly the intracellular Ca^2+^ concentrations that drive cardiac and skeletal muscle pathology. This sequence leads to downstream pro-inflammatory responses mediated by c-src, cyclooxygenase-2 (COX2), and C--C motif chemokine ligand 1 (CCL1) ([@bib115]; [@bib129]). AhR is also a key component for T cell development and activation mainly through the action of the Wnt/β-catenin pathway ([@bib102]). Xenobiotics induce regulatory T cell (iTreg) deficits, as found in autoimmune diseases such as multiple sclerosis ([@bib186]), through their impact on AhR.

Xenobiotics and viruses affect the immune cells (e.g. hematopoietic, myeloid, lymphoid) as well as the immune system barriers of the lung, gut, mucosal epithelia and the placenta through differential and variable AhR expression levels ([@bib138]). AhR deficiency and AhR dysregulation can impair the development of the aforementioned tissue barriers as well as the function of the adaptive and innate immune systems ([@bib151]). For example, smokers are more sensitive to viral and bacterial infection due to increased CYP1A1/CYP1B1 and matrix metalloproteinase-1 (MMP-1) expression through AhR activation by PAHs present in tobacco smoke, in a dose-dependent manner ([@bib123]).

The AhR molecular pathway regulates the immune response against bacterial and viral attacks. Therefore, it plays a role in the context of autoimmunity, infection, and cancer. Additionally, AhR modulates the circadian clinical manifestations of infectious diseases and opens potential opportunities for developing targeted therapeutics ([@bib58]). Hence, the circadian rhythm (evening)- observed exacerbation of clinical symptoms in malaria, bacterial sepsis, or seriously ill COVID-19 patients can be regulated by AhR.

AhR not only affects the immune responses to viral infection, but can also interact with viral proteins and affects viral latency. This suggests that AhR may modulate viral infection beyond influencing innate and adaptive responses ([@bib62]).

Xenobiotics and viruses acting through AhR can affect the gut-associated immune system and microbiome ([@bib58]) ([Fig. 2](#fig2){ref-type="fig"} ). The human gut virome, the 'missing link' between gut bacteria and host immunity, is a poorly understood component of the gut microbiota ([@bib139]). Diet, antibiotic use, and geographic variation can substantially affect the gut virome. Synthetic diets or diets with no vegetables and fruits have very low AhR activators, such as polyphenols and glucosinolates. These deficient diets can adversely affect the organogenesis of intestinal lymphoid follicles and innate immune cell homeostasis in the gut ([@bib68]; [@bib164]).Fig. 2Xenobiotics, viruses, bacteria, obesity and aging acting through AhR.Fig. 2

Exposure of the gut microbiota to various antibiotics has led to a substantial enrichment of the gut microbiome with phage-encoded genes that confer resistance to the administered and similarly acting antibiotics. This increased resistance, however, has created rather complicated biofilms promoting persistent infections or chronic inflammation ([@bib112]). Interestingly, microbiome is a highly dynamic ecosystem that evolves with age ([@bib98]). This also reflects the profound interpersonal diversity of the gut virome ([@bib111]). The virus--bacterial-host interactions in the gut play a protective role against gastrointestinal diseases such as necrotizing enterocolitis in preterm infants ([@bib119]), ulcerative colitis and Crohn\'s disease, and highlight the role of viruses in contributing to the initiation of inflammation ([@bib177]).

It is well established that pulmonary tissue is the most sensitive human tissue in COVID-19. Of particular interest is the fact that alveolar cells express the AhR at high levels at the basal matrix underneath the alveoli in which immune cells are found \[namely mast cells, lymphocytes, dendritic cells (DCs), and innate lymphoid cells (ILCs)\] ([@bib50]). This part of the respiratory system, however, is vulnerable to the effects of very fine particulate matter (especially matter with a diameter less than 2.5 μm, which is mainly produced by diesel engines, charcoal-burning, wood-burning, and industrial exhausts). This vulnerability is because particles of this size are able to bypass the protective mechanisms of the respiratory tract and accumulate in the alveolar tissue. If the particles are less than 0.1 μm, they can penetrate completely the alveolar cell membrane and enter the bloodstream. However, airborne particulate matter may act as AhR activators and thus trigger immune responses ([@bib167]).

Exposure to airborne particles (urban dust, PAH, diesel exhaust, cigarette smoke) by intranasal administration has been shown to increase pulmonary IL-17 expression ([@bib167]). Th17 cells are associated with autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and psoriasis ([@bib192]), but also glomerulonephritis, severe spontaneous colitis, asthma, dengue virus disease ([@bib71]), and swine flu determined by pandemic H1N1 influenza virus ([@bib9]). Epidemiologic studies have linked ambient particulate matter, nitrogen dioxide and other air pollutants exposure to immunologic diseases of the respiratory system (asthma and chronic obstructive pulmonary disease (COPD)), atopic diseases, allergic sensitization, eczema and polymorphisms of inflammatory cytokines via AhR-dependent mechanisms ([@bib113]). Furthermore, COPD has also been associated with an abnormal pulmonary and systemic immune response to tobacco smoking, although only the so-called "susceptible smokers" develop the disease ([@bib29]). Smokers and COPD patients are subpopulations with an increased risk of severe COVID-19, likely because of the enhanced airway expression of angiotensin-converting enzyme 2 (ACE2) receptor, the entry receptor for the SARS-CoV-2 virus, in lower airways ([@bib96]). Thus, many COVID-19 patients with COPD develop acute respiratory distress syndrome (ARDS), leading to pulmonary edema and lung failure. They also have liver, heart, and kidney damage, reflecting acute systemic inflammatory reaction syndrome and further multiple organ dysfunction syndrome ([@bib38]).

Cytosolic AhR levels and target genes, as well as AhR levels in the nucleus, might be useful markers of COVID-19 patient prognosis, based on previous studies reporting that AhR levels have been used for the diagnosis and prognosis in several aggressive tumors and multiple sclerosis patients ([@bib179]). The contribution of innate versus adaptive immune cells to lung pathology is still under investigation, as many inflammatory mediators are implicated ([@bib43]). Excessive or non-effective host immune responses due to long-term xenobiotic exposures or viral attacks can impair T cells and monocytes functionality, burden lung pathology and immunodeficiency, as observed in critical COVID-19 patients ([@bib196]).

Macrophages are critical for the development of inflammatory processes. These cells express the AhR, and several studies have corroborated their activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)*,* to produce and release modulatory chemokines and proinflammatory cytokines ([@bib173]). The AhR is a known modulator of antiviral pulmonary immunity. AhR activation by TCDD has been shown to decrease survival after infection with a nonlethal dose of influenza A virus, concomitant with doubling of pulmonary neutrophil influx and suppression of expansion and differentiation of virus-specific effector CD8^+^ T cells ([@bib173]). Thus, exposure to environmentally-derived AhR activators is associated with increased respiratory infections such as bronchial asthma and COPD ([@bib140]). COPD affects approximately 200 million people worldwide and is globally one of the leading causes of death. Smoking, biomass burning, air pollution, and inhalation of fine dust are contributing factors to COPD and atmospheric particulate matter ---a known carrier of AhR ligands--- can aggravate COPD ([@bib140]). PCBs also act through AhR, causing severe thymic atrophy and humoral immune suppression ([@bib152]).

2.2. Xenobiotics affect the developing and adult immune system {#sec2.2}
--------------------------------------------------------------

Immunological development is dependent on both genetic and environmental influences ([@bib169]). Both cellular and humoral immunity are factors that drive inter-individual variation in correlation with age, gender, and season. They all play a major role in shaping the immune profile analogous to lymphoid and myeloid cell level, B cell subsets, and Ig levels, or T cell immune traits as compared to the B cell immune traits. All these parameters are sensitive to toxic environmental exposures, especially in the adult immune system. The developing immune system can also be disrupted by early-life environmental insults, which may adversely affect the health of the exposed offspring later in life. These adverse effects could extend to following generations through epigenetic inheritance, thus weakening future generations' bodily defenses against infections ([@bib169]). The increased risk for injury to the developing immune system has been shown across several categories of drugs, chemicals, as well as heavy metals, some metalloids and mold toxins, through perinatal genome reprogramming, increasing the risk for adverse immune outcomes persisting into later life ([@bib169]). In particular, exposure to AhR agonists may cause persistent changes to immune responses that can affect subsequent generations, meaning that the environment of prior generations shapes susceptibility to pathogens and antiviral immunity in later generations ([@bib135]).

Developmental exposure to AhR-activating chemicals perturbs immune cell development, resulting in attenuated hematopoietic stem cell (HSC) differentiation and long-term self-renewal ([@bib144]). It also results in delicate deviations in the architecture of the crystal structure of AhR, thus contributing to increased incidence of autoimmunity and decreased responsiveness to infectious pathogens in later life, via gradual and long-term repression of AhR-mediated gene transcription ([@bib144]). Furthermore, long-term activation of AhR by TCDD has been shown to induce epigenetic changes in lymphocytes, especially T cells, leading to DNA hypermethylation and resulting in decreased CD8^+^ T cell antiviral immunity ([@bib13]). Conversely, early life exposure to TCDD enhances the CD4^+^ T cell response to viral infection in the lung, resulting in more significant broncho-pulmonary inflammation and reduced antiviral immunity ([@bib13]).

Exposure to a wide array of environmental chemicals, such as pesticides, heavy metals, and endocrine disruptors, may also affect the developing immune system. Pesticides, such as organochlorines (chlordane and DDT/DDE) organophosphates (diazinon) and carbamates (carbofuran) have been shown to induce developmental immunotoxicity ([@bib66]; [@bib143]). Prenatal exposure of humans to DDE has been associated with reduced levels of IgG and recurrent respiratory infections in infants, enhancing allergic responses via induction of Th2 cytokines ([@bib156]). The use of lead as a petrol additive, or more generally as an environmental contaminant, has adverse effects on the immune system, since the immune system appears to be quite sensitive to lead. Lead-induced skewing of immune responses has the potential to alter the incidence of asthma, autoimmunity, infectious diseases, or cancer ([@bib35]).

Early-life exposure to environmental and anthropogenic chemicals may result in reprogramming of the immune system. Exposure of the developing immune system to heavy metals, specifically lead, has been shown to adversely affect the generation of innate immune cells, such as macrophages and DCs ([@bib45]; [@bib52]; [@bib82]). Dysregulated macrophages and DCs effector functions reduce phagocytosis, lysosomal activation, produce excessively reactive oxygen species, and other inflammatory mediators (i.e., TNF-α, PGE~2~) by activation of the Erk/MAP kinase pathway, contributing thus to persistent Th2-biased immune responses and increasing the risk for inflammatory disorders and disease unmasked later in life ([@bib81]).

Endocrine disruptors, such as bisphenol A (BPA), have also been shown to alter immune system by interfering with hormone production and activity, and neuroendocrine axes ([@bib77]; [@bib131]). Perinatal exposure to low doses of BPA has been shown to alter the neonatal immune system and render it more susceptible to food intolerance ([@bib116]). Low-dose BPA exposure during the juvenile period of development may aggravate allergic airway inflammation by enhancing Th2 responses via disruption of the immune system ([@bib83]).

Long-term exposure to mixtures of anthropogenic pollutants such as nanomaterials (NMs), pesticides, BPA, phthalates, heavy metals, *particulate matter, PAH and toxins* during critical developmental periods, could hypothetically impact the immune system and increase viral infectivity, morbidity and mortality in children and adults ([@bib91]). Xenobiotics can impair a protective immune response, especially in organs expressing high ACE2 expressions, such as intestine and kidney.

The degree to which xenobiotics deregulate immune responses depends on cell-type and maturational state, especially in vulnerable population groups. Both inflammatory and regulatory gene expressions via cross-talk between transcriptional (e.g. AhR and NF-κB), xenobiotic response elements activation and other posttranslational and epigenetic alterations, together with viral immunotoxicological engagements, contribute to unwanted complications on macrophages, dendritic cells, the cytolytic activity of murine NK cells, innate lymphoid cells and Foxp3^+^ regulatory T cells ([@bib136]).

3. Long-term low-dose exposures to mixtures of anthropogenic chemicals may affect the human health through dysregulation of the immune system {#sec3}
=============================================================================================================================================

Exposure to single chemicals during development has been shown to impair immune responses. However, under real-life exposure scenarios, humans are widely exposed to mixtures of numerous chemicals and other stressors, such as radiation, sound, biotoxins, etc., present in different sources (environment, diet, workplace). Thus, the relevant exposure framework for evaluating potential impairment of the immune function relies on assessing mixtures of chemicals (and other toxic stressors) rather than single chemicals in our changing environment. According to this approach, exposure to chemical mixtures during development could be more detrimental to the immune system than exposure to single chemicals, depending on the nature of the chemicals and their dosages. While the developmental stage is the most vulnerable period to chemical toxicity, exposure during non-critical periods should also be considered. Furthermore, it should be highlighted that low-dose disruptive effects of chemicals on key biological pathways and mechanisms in certain subpopulations may enhance susceptibility to diseases.

The immune system recognizes engineered nanomaterials (NMs) as foreign bodies, resulting in multilevel responses that can range from acute to chronic. These responses can range from immune-stimulatory to immunosuppressive, but can also vary in host toxicity and/or reduced therapeutic efficacy of conventional pharmaceuticals ([@bib41]; [@bib78]; [@bib118]). NMs-induced immune activation may increase the incidence of allergic reactions, inflammatory responses, or autoimmunity. Additionally, NMs-induced suppression may reduce maturation and proliferation of immune cells, resulting in increased susceptibility to infectious diseases or tumor growth.

In nanotoxicology, numerous studies clearly demonstrate that multi-walled carbon nanotubes (MWCNT) and inhaled particulate matter (PM) induce lung injury ([@bib78]; [@bib132]) through acute and chronic inflammation, granuloma formation, and substantial interstitial lung fibrosis. MWCNT and PM can also exacerbate asthma-like conditions via innate pathways such as TLRs that trigger the generation of IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). MWCNT also induce epithelial damage resulting in IL-33 release, which in turn promotes innate lymphoid cell recruitment and the development of IL-13-dependent inflammatory response ([@bib7] *)*.

A number of studies similarly linked MWCNT-induced oxidative stress, phagolysosomal permeabilization, cathepsin B release, NLRP3 inflammasome assembly, and caspase-1 activation with the secretion of important regulatory cytokines (e.g., IL-1β and IL-18). Titanium dioxide nanomaterials, long carbon nanotubes, asbestos and silica, affect innate immune activation through reactive oxygen species (ROS) generation, cathepsin B activity that activate Nalp3 inflammasome and induce Il-1α and IL-1β secretion by caspase1, autophagy and lung fibrosis ([@bib125]). These findings highlight that inflammasome activation and autophagy induction may occur via pathways other than the well-established mTOR pathway ([@bib125]).

Pesticides can impact human health and the environment adversely through cellular and extracellular, direct and indirect mechanisms in a complex and synergistic mode. Extracellularly, synthetic pesticides activate primarily receptors of cytokines ([@bib51] *)* ([Fig. 3](#fig3){ref-type="fig"} ). These key receptors, via secondary signaling pathways such as TLR/MYD/NF-kB, P38 MAPK/AP-1, AhR, ER/FFAs/PPARγ, B-cell receptor or Cyclin D signaling pathways, directly and indirectly, alter transcriptionally and epigenetically global gene expression ([@bib171]) ([Fig. 4](#fig4){ref-type="fig"} ).Fig. 3**Molecular and cellular mechanisms triggered by long term pesticide exposure.** Pesticides induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6) of macrophages, aromatase expression, growth factors and oxidative stress, oestrogenicity, carcinogenesis, DNA damage, genomic, epigenetic changes, obesity and abnormal embryo development.Fig. 3Fig. 4Transcriptional alterations induced by selective pesticides.Fig. 4

Pesticides also, affect the metabolism of Ca+2, vitamin D and iron, disrupt redox biology ([@bib47]), activate proteasome system, alter microbiome ([@bib75]), increase PGE~2~ via COX2, increase Th 1 cytokines and decrease Th 2 cytokines, leading to T-cell immaturity. The pesticidal loosening of tight junctions increases the intestinal permeability and disrupts the integrity of vasogenic homeostasis and vascular permeability, thus increasing translocation of bacteria to distal organs and resulting in bacterial infectivity ([@bib153]). Pesticides also disrupt redox biology, reduce antioxidant enzyme activities, increase reactive oxygen species (ROS) and oxidative stress, which may impact the immune system function because of the cross-talk between oxidative and pro-inflammatory pathways. In addition, pesticides can induce ATP and energy depletion and DNA instability through DNA damage or epigenetic alterations, sister chromatid exchanges, telomere shortening, diverse mutations, and premature cell death, which also impact the immune system function ([@bib32]; [@bib49]; [@bib161]; [@bib165]).

In any case, given the plethora of physiological pathways and functions that can be disrupted by chemical exposures, the current risk assessment approach based on the assessment of individual substances is insufficient to address exposure to chemical mixtures under real-life conditions ([@bib84]; [@bib162]; [@bib63]).

4. Molecular and cellular mechanisms of SARS-CoV-2 cell attack {#sec4}
==============================================================

SARS-CoV-2 is a member of the coronavirus family that has a single-stranded RNA genome of positive sense. This gene encodes four structural proteins, namely spike glycoprotein (S), a small envelope protein (E), matrix glycoprotein (M) and nucleocapsid protein (N) ([@bib97]). The entry of the virus into cells is mediated by the S protein, in particular by attaching its surface unit (S2) to ACE2, an enzyme present in primarily type II pneumocytes (lung alveolar epithelial cells). Then the S protein is cleaved by cellular proteases and the viral capside is fused with the cellular membrane, thus allowing intracellular translocation of SARS-CoV-2 coupled with ACE2 by endocytosis ([@bib18]). This is followed by massive intracellular replication of SARS-CoV-2, which then undergoes exocytosis where it binds again to ACE2, thus entering into a vicious cycle ([@bib1]) Furthermore, after endocytosis of the SARS-CoV-2/ACE2 complex, surface ACE2 is down-regulated, resulting in unopposed angiotensin II accumulation ([@bib166]). The binding affinity of specific receptor binding of S protein is related to virus infectivity and pathogenicity (Li et al., 2020<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093363)>). In this regard, ACE2 genetic polymorphisms and expression levels in different tissues might alter host susceptibility to COVID-19 by affecting the interaction with SARS-CoV-2 S-protein.

ACE2 belongs to the renin-angiotensin-aldosterone system (RAAS), which contributes to the pathophysiology of hypertension and cardiovascular/renal diseases by maintaining homeostasis of blood pressure, electrolyte balance and inflammatory responses ([@bib18]). ACE2 can be considered as a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1--7), which exerts vasodilatory, natriuretic/diuretic, anti-inflammatory, and antifibrotic effects via Mas receptor (MasR) ([@bib1]; [@bib166]).

ACE2 is highly expressed in the lung, where it appears to exert a protective role in acute lung injury as loss of pulmonary ACE2 function has been associated with acute lung injury. Hence, the binding of SARS-CoV-2 with ACE2 neutralizes the advantageous physiological effects of this enzyme. Attenuation of ACE2 catalytic function alters RAAS system activity, resulting in enhanced inflammation and vascular permeability observed in the pathogenesis of inflammatory lung disease, eventually leading to acute lung injury and adult respiratory distress syndrome as observed in patients with severe COVID-19 ([@bib21]). Hence, local activation of the RAAS may mediate lung injury responses to viral insults ([@bib166]). Indeed, when angiotensin I and angiotensin II receptors (AT1R and AT2R, respectively) are activated, they lead to the increased expression of proinflammatory mediators (e.g., IL-6), triggering an inflammatory process in the lungs and other organs. In particular, AT1R activates the transcription factors NF-kB and activator protein 1 (AP-1), which in turn increases cytokine expression, apoptosis, vasoconstriction, fibroproliferation, retention of Na+, and the enhancement of lung injury. The endogenous angiotensin II inhibits alveolar fluid clearance and dysregulates epithelial Na^+^ channel (ENaC) expression via AT1R, contributing to alveolar filling and pulmonary edema ([@bib18]).

ACE inhibitors and angiotensin-receptor blockers (ARBs) have shown to up-regulate ACE2 expression in animal studies, thus increasing the availability of target molecules for SARS-CoV-2. These considerations have led to speculation that ACE inhibitors and ARBs might be harmful in patients with Covid-19. However, a number of studies conducted in different populations and with different designs have come to the conclusion that ACE inhibitors and ARBs are unlikely to be harmful in patients with Covid-19 ([@bib72]). Conversely, because of the protective effects of ACE2 on acute lung injury and chronic diseases, the development of drugs enhancing ACE2 activity might be an approach for the treatment of COVID-19 ([@bib21]). The aforementioned speculations should not be regarded as evidence to prescribe or not these drugs in patients with Covid-19. Clearly, randomized clinical trials are warranted to shed light on this apparent paradox.

The early onset of rapid viral replication may cause massive epithelial and endothelial cell apoptosis and vascular leakage, triggering the release of exuberant pro-inflammatory cytokines and chemokines ([@bib188]). The excessive immune reaction produced by SARS-CoV-2 infection in the host can lead in some cases to the so-called 'cytokine storm' or 'cytokine release syndrome'. This syndrome can be triggered by a variety of factors, such as infections and certain drugs, and consists of an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction resulting in an extensive tissue damage. The main cytokine responsible of this storm is IL-6, which is produced by activated leukocytes and acts on a large number of cells and tissues ([@bib17]).

The Toll-Like Receptor (TLR) signaling pathway is evolutionarily conserved and functionally linked to innate immunity. Signaling results in nuclear translocation of the transcription factor NF-κB, which regulates the expression of distinct genes in immunity or development ([@bib4]). TLR has been implicated in the pathogenesis of airway disease resulting from respiratory virus infections, with TLR signaling leading to the activation of type I interferons (IFN-α and IFN-β), proinflammatory cytokines (IL-6, TNF, IFN-γ, and CCL5), and interferon-stimulated genes ([@bib159]). The binding of SARS-CoV-2 to the TLR activates the its downstream signaling pathway, causing the release of pro-IL-1β (which is cleaved by caspase-1). This is followed by inflammasome activation and production of active mature IL-1β, which is a mediator of lung inflammation, fever and fibrosis ([@bib26]).

5. Xenobiotics and viruses have common and more than one mechanisms of action {#sec5}
=============================================================================

Chronic organochlorine, organophosphate, paraquat and pyrethroid exposures have been linked to Parkinson\'s disease and other neurodegenerative diseases through mitochondrial dysfunction, oxidative stress, and apoptosis via cell signaling pathways ([@bib16]). Some pesticides have been reported as potential risk factors of chronic erectile dysfunctions ([@bib134]), probably via NADPH oxidase/ROS production and reduced bioavailability of NO ([@bib73]). Experimentally, DDE (a metabolite of DTT) exposure exhibits a diabetogenic potential, with an underlying immunomodulatory mechanism likely via cytokine cascades, or disrupted glucose homeostasis ([@bib19]). Cardiovascular toxicity has also been reported following exposure of zebrafish to deltamethrin ([@bib108]).

Adjuvants in pesticides formulations are used to increase the pesticidal effect of the active ingredient. However, this is a constant underestimated factor of pesticide mixture chronic toxicity ([@bib109]). For instance, it has been shown that animals subjected to concomitant exposure to certain fungicides, such as ergosterol biosynthesis inhibitors, are able to increase the pyrethroid and neonicotinoid insecticides cytotoxicity up to 1000- and 8-fold respectively. This combined exposure may result in enforced lipogenesis and/or oncogenic transcriptional alterations, which may not occur with individual chemicals ([@bib157]).

Xenobiotics and viruses activate similar transmembrane receptors of cytokines, toll-like receptors, growth factors, secondary signaling pathways, such as TLR/MYD/NF-kB, P38 MAPK/AP-1, AhR, hormone receptors, B-cell receptor or Cyclin D signaling pathways, directly and indirectly and thus alter the global gene expression transcriptionally and epigenetically ([@bib26]; [@bib51]). Xenobiotics and viruses affect the metabolism of Ca^+2^, K^+^ and Cl^−^ efflux, vitamin D, iron and coagulation factors, disrupt redox biology, activate proteasome and the inflammasome system, alter microbiome and virome, increase PGE~2~ via COX2, and increase Th 1 cytokines, resulting in T-cell immaturity ([@bib54]; [@bib75]).

Xenobiotics and viruses disrupt the redox biology, reduce antioxidant enzyme activities, increase reactive oxygen species (ROS) and oxidative stress, ATP and energy depletion, DNA instability through DNA damage or epigenetic alterations, premature cell death and ageing ([@bib54]; [@bib75]; [@bib105]). Furthermore, both xenobiotics and living microorganisms may contribute to increased resistance to treatments, bacteria or viruses aggressiveness, communicable diseases and decreased vaccination effectiveness.

Viral infections and chemical exposures can produce pro-inflammatory mediators that, if sustained over time, result in chronic inflammation in target organs. This condition often entails tissue damage, increased mutation rate and genomic instability, which represents a cancer-prone microenvironment ([@bib80]). In cardiovascular morbidity, xenobiotics and viruses have been found to increase chemokines, cytokines, heart mitochondrial GPx activity, DNA damage, cholesterolemia, expression of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and pro-coagulant activity, ROS, TNF-α and TGF-β, protein and lipid oxidation in heart cells, endothelial dysfunction, and decreased mitochondrial GSH levels, resulting in hyper-coagulability and thrombosis ([@bib190]).

Both xenobiotic and viral immune morbidity are due to alterations in gene mRNA and protein expression via pro-inflammatory cytokine, chemokine, kinase and neuroendocrine signaling, activation of T-cells, disruption of gut microbiota and immune homeostasis ([@bib53]; [@bib74]). These reprogram the cell cycle control in the Golgi region via cycline gene alterations and premature cell death ([@bib22]). *C*rohn\'s disease, rheumatoid arthritis, autoimmune thyroidopathies, systemic lupus erythematosus, psoriasis, fibromyalgia-osteoarthritis, chronic pain, and multiple chemical hypersensitivity have been associated with pesticide exposure ([@bib46]; [@bib93]; [@bib184]). Global immune deficiency, vaccine and drug ineffectiveness, bacterial and virus virulence, cancer aggressiveness, increased chronic inflammatory pathologies are associated with various pesticide adverse immune effects.

Additionally, pesticide exposure in neonates and children is correlated with alterations in B-cell maturation, rapid cell proliferation, disruptive homeostasis of the pro-oxidant agents, altered fecal microbiota composition, cytokine expression and antioxidant defenses, steroids and genomic alterations ([@bib55]; [@bib99]; Mona et al., 2012). Both NMs and viruses can affect the adaptive immune response by direct activation of antigen-presenting cells (APCs), including B cells, dendritic cells, macrophages, helper and cytotoxic T cells, and can contribute to both intracellular and extracellular immune response deficiency to pathogens but also to increase t[issue-specific autoimmunity](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022068){#intref0015}, observed in autoimmune diseases ([@bib76]). Both hydrophobic nanoparticles \<5 nm and viruses dictate the immune response exhibiting the greatest expression of inflammatory cytokines ([@bib114]).

Moreover, many nodal points used by viruses and chemicals to generate, develop and disperse pathologies and diseases have been used over the last three decades individually or in combination as targets for modern checkpoint therapies through monoclonal antibodies in order to address these diseases ([@bib127]; [@bib59]). Transcription factors, membrane receptor signaling pathways, and protein kinase signaling pathways, are all key players of xenobiotic-induced cancer in adults ([@bib40]) and *children (* [@bib60]), hematological and lymphoid malignancies ([@bib95]), Alzheimer\'s disease and Parkinson\'s disease ([@bib3]) and stroke ([@bib160]). Furthermore, this knowledge has also been valuable for molecular-oriented anti-cancer therapy ([@bib100]).

ACE2 expression has been shown to be upregulated by infection with SARS-CoV-2 ([@bib175]). However, the relation between ACE2 and SARS-CoV-2 virulence is complex and it is attracting extreme interest currently ([@bib65]), following concern about the potential ability of some anti-hypertensive drugs, such as ACE-inhibitors and angiotensin-receptor blockers (ARBs) to increase Covid-19 severity and case fatality rate ([@bib31]). This is a clear example of environmental toxins laying the groundwork for increased susceptibility to COVID-19 (and other viral diseases), and subsequent treatments exacerbating the severity of COVID-19, and is why elimination of the environmental toxin is the much preferred route.

On the other hand, the relation between ACE2 levels and SARS-CoV-2 virulence might go in both directions, i.e. both high and low ACE2 activity could theoretically increase Covid-19 severity ([@bib57]). Therefore, more research is urgently needed about the interaction between the ACE-inhibitor/ARB use and the susceptibility to increased Covid-19 severity. Observational studies are currently underway on this issue, and need to be expanded. In the meantime, caution has been suggested by scientific and professional societies about any modifications to current anti-hypertenive drug therapy based on ACE-inhibitors and ARBs in people with high blood pressure, in the absence of convincing clinical evidence of their benefits against severity of Covid-19 ([@bib44]; [@bib42]).

It has been posited that the antimalaric drugs chloroquine and hydroxychloroquine reduce glycosylation of ACE2, thus preventing SARS-CoV-2 from binding to host cells ([@bib34]). Chloroquine has also been shown to inhibit quinone reductase 2, an enzyme that functions prominently in sialic acids biosynthesis ([@bib122]) and critical components of ligand recognition ([@bib92]). Many trials have recently been initiated on the real clinical usefulness of these drugs, which have been suggested to be useful in early therapy and even in the prevention of Covid-19. However, based on their established and potentially very serious side effects, these drugs should not be initiated until there is clear evidence of their efficacy for the treatment of Covid-19.

In addition, given that SARS-CoV-2 entry into the host cells is mainly mediated by the endocytic pathway, chloroquine seems effective in blocking endocytosis and/or inducing viral entrapment into the lysosome. The latter can be achieved by neutralizing the endosomal pH, thus favoring virus--endosome fusion, inhibit lysosomal protease activity, and prevent the cleavage of S protein and therefore viral entry into the host cell ([@bib189]). Chloroquine may also thwart viral protein maturation, block the recognition of viral antigens by dendritic cells, and increase cytotoxic CD8^+^ T-cell activity to viral antigens. In addition, it blocks phosphorylation (activation) of the p38 mitogen-activated protein kinase (MAPK) and caspase-1 ([@bib154]) in THP-1 cells, both of which are required for SARS-CoV-2 and other viruses replication ([@bib14]). Moreover, chloroquine affects immune system activity by mediating an anti-inflammatory response, which might reduce damage due to the cytokine storm. Chloroquine inhibits IL-1β mRNA expression in THP-1 cells, reduces IL-1β release, IL-1 and IL-6 cytokines in monocytes/macrophages, and IFNα, IFNβ, IFNγ, TNFα, IL-6 and IL-12 gene expression ([@bib34]). Lysosomotropic agents, ammonia chloride and bafilomycin A, have been found to reduce the transduction on 293/hACE2 cells by SARS-CoV-2 S, and thus inhibit the SARS-CoV-2 entry into cells through endocytosis ([@bib172]; [@bib124]).

Finally, the newly-introduced anti-viral agent Remdesivir was found to be beneficial against SARS and MERS in animal models ([@bib67]). Remdesivir is an adenosine analogue, antagonizing adenosine for RNA-dependent RNA polymerase, causing their premature viral RNA termination ([@bib150]). However, as Remdesivir is a prodrug, it has to be metabolized in order to reach its active form GS-441524. Its clinical significance was proved during the West African Ebola virus epidemic of 2013--2016 and the Kivu Ebola epidemic in 2018 ([@bib178]). Given its promising effectiveness against previous corona-viruses, Remdesivir has also been tested against COVID-19. According to various studies, favorable outcome is to be expected from animal use given the in-vitro efficiency of the drug ([@bib174]). Although Remdesivir has led to quick recoveries in symptoms of Covid-19 patients in a clinical trial, results from its Phase III trial involving severe Covid-19 patients are expected to be available soon.

6. Approaches and challenges to tackle the Covid-19 epidemics/pandemics {#sec6}
=======================================================================

It is well understood that COVID-19 outbreak and current policies are based on regulations; the main strategy worldwide mirrors and expands the strategy used in the prior SARS pandemic to limit the spread of the pandemic: 'Stay at home'/quarantine. This approach primarily does not account for human real-life needs scenarios, lacks realism as a directive for subsequent new viral epidemics or pandemics, does not provide the protections afforded by 'herd immunity, does not meet current and future needs in health and safety of the global population, and adversely impacts development of production and economy worldwide. The only advantages are 1) flattening the contagion curve through social distancing and lockdowns and 2) avoiding hospitals (and Intensive Care Units) overwhelmed by Covid-19 cases.

The global spending on cancer therapies, cholesterol-lowering drugs, malaria, spina bifida and anencephaly, osteoporosis, vaccine market and diabetes nowadays exceeds \$ 5 trillion USD and, according to [@bib180] is expected to grow at a compound annual growth rate of 5% in the next ten years period ([@bib181]). According to [@bib180], the global total 2019 health cost is about 10 trillion USD, 10% of Gross National Product (GDP) and 1080 USD per capita ([@bib182]). The total global cost for COVID-19 will be unknown for months, and it will likely have a substantial secondary cost burden for decades.

As health authorities are developing effective measures to stem the health effects of COVID-19, uncertainties remain regarding both the virus-host interaction and the evolution of the epidemic. The spatial-temporal features of the pandemic, the attempts to conceal the origin and the first medical data from Wuhan, the route and the difference of the spread of the virus, the criteria used to assign deaths to the COVID-19 category, the reduced mortality-to-incidence ratio as testing rises and more patients are identified, the non-observance of individual protection measures and treatment of mild *Covid-19* cases *in new* temporary *hospitals*, the intensified competition and mutual accusations between USA and China, the lack of scientific data on treatment and vaccine, difficulties in verification of alleged or attempted biological attacks by the use of living-biologically modified - viral agents, all raise insecurity and reasonable questions worldwide.

As of mid-March 2020, many countries in the world are on partial lockdown to control the pandemic (COVID-19) spread, and the only effective 'treatments' at this time are good hygiene (washing hands), wearing a mask, and quarantine. Although quarantine may reduce the spread of the virus, it may impose the self-medication at home for chronic diseases without medical diagnosis and treatment, increase the risk of adverse complications of cardiovascular, metabolic, autoimmune and psychiatric diseases, shifting thus the health cost from public providers to patients. Scientists in fields of public policy have presented combined tactical and strategic treatment approaches that aimed at preventing and reversing COVID-19 and other diseases, including treatment repurposing as well. Optimally, the tactical and strategic approach components would be implemented in parallel, to provide benefit from the synergies of the combined approach This combined approach would allow the vulnerable to survive the near-term potentially lethal effects of SARS-CoV-2 exposure through tactical treatments, and would allow the most vulnerable and the larger population to be more resistant to future viral attacks of all types through strategic treatments ([@bib88]).

7. Effects of diet on immune system and role of nutrient supplements on infected vulnerable groups {#sec7}
==================================================================================================

The immune system is remarkably dynamic throughout life in relation to its components' number and its function. Interestingly, older adults exhibit a decline in immune function -known as immunosenescence-resulting in increased susceptibility to infectious diseases and a higher risk of serious complications than younger people, reflecting altered acquired and innate immunity ([@bib28]). Aging is associated with altered T cell function, decreased thymic output and thymic involution, and reduced numbers of naive T cells ([@bib10]) and micronutrient deficiencies. All these elements play key roles in increasing inflammation and its resulting morbidity and mortality ([@bib145]). Immune function may be improved in immune competent adults, particularly those over 65 years old, by restoring deficient micronutrients, such as vitamins A, C, D, E, B2, B6, and B12, folic acid, iron, selenium, and zinc to optimal ([@bib103]). Adequate intake and bodily levels of these micronutrients has been shown to be critical in reducing risks stemming from inflammatory and non-communicable diseases ([@bib110]).

Nutritional modulation of the immune system is also associated with reduction or delayed onset of immune-mediated chronic diseases. Several micronutrients and dietary components have been shown to play specific roles in the development and maintenance of an effective immune system. For example, arginine is necessary for the nitric oxide generation by macrophages, and vitamin A and zinc are known regulators of cell division. Vitamin E is both an antioxidant ([@bib94]) and protein kinase C activity inhibitor ([@bib23]). Dietary and supplementation interventions enriching the gut microbiome, such as the use of probiotics and prebiotics ([@bib64]), may be needed to help enhancing or restoring a healthy gut microbiome. In addition, diets lacking vegetables may decrease the diversity of nutrients reaching the gut microbiome. This in turn alters epithelial integrity resulting in increased permeability or 'leaky gut', allowing immune cells within the gut-associated lymphoid tissue to be directly exposed to intraluminal nutrients or elements of the gut microbiota. A great example of altered gut permeability induced by micronutrient status is that of vitamin D. Specifically, vitamin D-deficient diets are found to be responsible for increased epithelial permeability due to dysfunctioning tight junctions, resulting in both acute and chronic gut inflammation ([@bib12]; [@bib147]). Optimal probiotic bacterial composition has been shown to effectively reduce inflammation, characterized by reduction of proinflammatory Th1 and Th17 cytokines, such as IL-17 and IFN-γ, and concomitant increases in the levels of inflammation-resolving cytokine, such as IL-10 ([@bib146]). On the other hand, prebiotics can be used not only as substrates for bacterial metabolism but also to enhance barrier function. The unparalleled importance of natural and well-balanced diets has been also highlighted vis-à-vis infant formula consumptions. It is well established that breastfeeding affords passive immunity to the infant via transfer of antibodies, growth factors, and cytokines to the offspring ([@bib158]; [@bib133]). Breastmilk is also enriched with microbiota thatpromote the maturation of gut-associated lymphoid tissue ([@bib39]), playing a key role in development of the immune system during thymus maturation, particularly for T cell function. In breastfed infants, complementary feeding with prebiotics for optimal microbiome maintenance has been proposed ([@bib107]).

The Western-type diet (described as a diet rich in processed sugars, trans- and saturated-fats, but low in complex carbohydrates, fibers, micronutrients, and other bioactive molecules such as polyphenols and omega 3 polyunsaturated fatty acids) has been shown to predispose to inflammation, likely by increasing the uptake of lipopolysaccharide (LPS) from gut microbes secondary to altered gut permeability and increased leakiness ([@bib168]; [@bib198]). Although activation of TLR4 by LPS may cause inflammatory response, a number of nutrients, such as long-chain omega 3 polyunsaturated fatty acids, have been shown to thwart TLR4 activation, thus attenuating inflammation ([@bib142]). In contrast, a Mediterranean-type diet, which is rich in certain foods (vegetables, fruit, nuts, legumes, fish, 'healthy' dietary fats such as virgin olive oil), has been shown to be associated with lower risk for chronic diseases, including cancer, cardiovascular disease, and neurological disorders ([@bib37]). These effects have been attributed to immune-modulation and the anti-inflammatory properties of various polyphenols and other bioactive compounds inherent to these foods, especially fruits and vegetables ([@bib187]). Νutrients from genetically modified organisms (GMOs) affect the adaptive immune response because the cellular ability for specific recognition of a genetically modified protein is lacking. There is no 'memory' on repeated exposure, resulting in allergic reactions observed in consumers after consuming modified plants. One example is the "Starlink" maize, which was engineered with genetic information from Bacillus thuringiensis to increase the plant\'s resistance to various insects ([@bib117]; [@bib163]; [@bib194]). Except for xenobiotic and GMOs allergenicity, there are genetic hazards arising from the inserted gene, its expressed protein per se, and secondary or pleiotropic effects on other gene expression. This results in disruption of natural genes in the manipulated organism ([@bib6]).

Micronutrients, such as Zn and Selenium, have important catalytic and structural roles as co-factors in numerous proteins involved both in adaptive and innate immune response ([@bib70]). Significantly, selenoproteins regulate immunity in numerous infectious diseases, including human immunodeficiency virus infection ([@bib5]).

Under acute infections, such as COVID-19, glutamine consumption rate by immune cells increases, especially in rapidly dividing cells of the immune cells. Thus, glutamine supplementation in critically ill patients is necessary ([@bib30]). Finally, the activation of vitamin D nuclear receptor (VDR) by 1,25(OH)2D3 (calcitriol, the active form of vitamin D) is found to enhance both the innate and adaptive immune response ([@bib176]). This can be very important in cases of infectious diseases in the elderly, such as COVID-19, where the patient is probably suffering from exhausted vitamin D.

8. Discussion {#sec8}
=============

Atmospheric pollutants from power plants, industries, transport, fuel combustion of military missiles and aircrafts, weapon of mass destruction such as chemical, nuclear and biological weapons ([@bib130]), spacecrafts, electromagnetic fields ([@bib86]) and irradiation from nuclear weapons, nuclear power plants and modern technology radiation ([@bib87]; [@bib85]) are environmental factors that seriously harm health of humans, and other forms of life ([@bib104]). Historically, viruses may have been used in the past as biological weapons. Today, despite the 'Biological and Toxins Weapons Convention' that entered into force in 1975, it is known that many countries are still working on and stockpiling biological weapons ([@bib24]). Chemicals, metals, particulate matter, nanoparticles, anthropogenic climate change, and increased UVB radiation disrupt health, ecosystems and environment. These toxins, along with the toxic modern lifestyle and smoking, constitute an ideal man-made environment for the development, and spread, of modern diseases, including the new viral epidemics/pandemics that occurred during the two last decades ([Fig. 5](#fig5){ref-type="fig"} ).Fig. 5The common mechanisms through which exposure to different stressors and viruses leads to inhibition of immune system.Fig. 5

We have described the common intracellular mechanisms that environmental and anthropogenic pollutants, as well as the SARS-CoV-2, use for their immunotoxicity and mechanism-based treatment approaches. Βasic and applied immunotoxicology can enhance public health and provide significant advantages in the prevention and treatment of epidemics/pandemics and chronic diseases.

While several animal species may harbor SARS-CoV-2, the precise animal reservoir has yet to be confirmed. It seems likely that a spike mutation, which probably occurred in late November 2019, triggered transmission of the virus to humans ([@bib17]). Τhe current anti- SARS-CoV-2 therapies used in some patients have been unable to counteract disease progression and to save patients' lives. Since the S2 subunit of SARS-CoV-2 is highly conserved, it could be a target for antiviral (anti-S2) drugs; however, the potential for viral mutations may be responsible for future disease relapses ([@bib17]). In this study, we emphasize that in addition to the urgent measures that are necessary to interrupt the coronavirus transmission from farming animals to humans, there is also a need to improve the current global strategy for energy management and other factors that may adversely affect the immune system of the human, and thereby increase the risk of both infectious and chronic-degenerative diseases. Exposures to large classes of xenobiotics have a triple impact on the immune system. First, xenobiotics promote immunomodulatory effects in immune cells. Second, xenobiotics increase the range of immunotoxicity of human-associated micro-organisms or new viral and microbial attacks. Third, xenobiotics may reduce vaccine efficacy.

Global health cost and COVID-19 effects on the world economy, health systems, and production are massive currently, and will be far more massive when a final accounting is performed. We recommend application of massive COVID-19 screening tests as an important step for properly 1) recording the extent of the COVID-19 outbreak and, through evidence-based corrective actions, 2) delaying the spread of the pandemic. Given the guidance of the health authorities to transfer COVID-19 patients into hospitals only when presenting fever and dyspnea, it appears that for all admitted patients, and especially for ICU patients, the inflammosome is already at an advanced stage precluding effective treatment. Accordingly, novel AhR-mediated immunotherapies for a plethora of immune-associated diseases/disorders should be pursued.

Conclusively, additional common safety factors need to be added when calculating COVID-19 prevalence and infectivity, including the cooperation of healthcare providers and the scientific community experts. The use of a self-managed qualitative and quantitative evaluator for COVID-19 spread is also a realistic suggestion, keeping in mind that the increased incidence in COVID-19 outbreak in Italy, Spain, Iran, Turkey, USA and United Kingdom appears to have a close correlation to probably inadequate and delayed implementation of uniform antivirus measures, despite the socio-economic, racial, demographic, cultural and administrative characteristics of each country. New investigations into both genetic and environmental fields of immunotoxicology will advance our understanding of immune function, provide the foundation for the development of novel immunotherapeutics and, more importantly, decrease the effect of immunological risk factors.

9. Conclusion {#sec9}
=============

This paper highlights that environmental-related diseases (e.g., energy-metabolism-immune mediated obesity, type II diabetes, metabolic syndrome and cancers) and infectious diseases (e.g., parasitic, influenza or coronavirus-related epidemic or pandemic) share the same pathogenic mechanisms at the molecular level, particularly the AhR pathway. Viral epidemics and pandemics, in addition to causing significant morbidity and mortality, can challenge societal structure and healthcare. As novel viruses continue to emerge, novel therapies and preventative measures must be sought. Understanding and optimizing host cell health and viral infectivity parameters are critical steps for any successful cytolytic virology.

Χenobiotics immunotoxicity, and immune deficiency, deviation or dysregulation affect immunological development, and induce immuno-dependent diseases that are transmitted transgenerationally to offspring. The best long term therapy to mitigate the effects of anthropogenic pollutants related to immune deficiency and fatal viral outbreaks is to introduce much more stringent regulation on the emissions resulting from unabated introduction of modern technologies into our environment, our workplace, and our daily life.

In addition, integrated chemical management, economic and political measures to reduce industrial pollution, greenhouse gases and the effects of climate change on human and environmental health (the 'one health' goal), new technology systems should continue to provide positive outcomes for immune system function and chronic disease prevention, as well as for restriction of viral and bacterial invasion and aggressiveness. Currently, the public health measures based on social distancing, appropriate quarantine, and increase of COVID-19 diagnostic tests globally are the necessary options for our defense against the SARS-CoV-2 pandemic, although they don\'t contribute to the potentially protective 'herd immunity'.

CRediT authorship contribution statement {#sec11}
========================================

**Aristidis Tsatsakis:** Conceptualization, Methodology, Writing - review & editing, Supervision. **Demetrious Petrakis:** Conceptualization, Investigation, Formal analysis, Writing - original draft. **Taxiarchis Konstantinos Nikolouzakis:** Conceptualization, Investigation, Formal analysis, Writing - original draft. **Anca Oana Docea:** Conceptualization, Investigation, Formal analysis, Writing - original draft. **Daniela Calina:** Investigation, Formal analysis, Writing - original draft. **Marco Vinceti:** Investigation, Formal analysis, Writing - original draft. **Marina Goumenou:** Investigation, Formal analysis, Writing - original draft. **Ronald N. Kostoff:** Conceptualization, Methodology, Writing - review & editing, Supervision. **Charalampos Mamoulakis:** Investigation, Formal analysis, Writing - original draft. **Michael Aschner:** Conceptualization, Methodology, Writing - review & editing, Supervision. **Antonio F. Hernández:** Conceptualization, Methodology, Writing - review & editing, Supervision.

Declaration of competing interest
=================================

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

[^1]: equally contributed to the manuscript thus share the first authorship.
